1,3-bis-(trifluoroacetamido)-isopropanol | 97231-31-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1,3-bis-(trifluoroacetamido)-isopropanol
• 英文别名: 1,3-bis-(trifluoroacetamido)isopropanol；1,3-bistrifluoroacetamido-2-propanol；1,3-bis-(trifluoroacetamido)-2-propanol；2,2,2-trifluoro-N-[2-hydroxy-3-[(2,2,2-trifluoroacetyl)amino]propyl]acetamide
• CAS: 97231-31-7
• 化学式: C₇H₈F₆N₂O₃
• 分子量: 282.143
• InChiKey: XGJMDMQAOYCRLK-UHFFFAOYSA-N

物化性质

• 沸点：
  384.9±42.0 °C(Predicted)
• 密度：
  1.511±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  1,3-bis-(trifluoroacetamido)-isopropanol 在 Jones reagent 、 tetraphosphorus decasulfide 作用下， 以 水 、 丙酮 、 甲苯 为溶剂， 反应 22.0h， 生成 2,2,2-trifluoro-N-((2-(trifluoromethyl)thiazol-5-yl)methyl)ethanethioamide
  参考文献：
  名称：

  [EN] PROCESS FOR MAKING HEPATITIS B CORE PROTEIN MODULATORS
  [FR] PROCÉDÉ DE PRODUCTION DE MODULATEURS DE PROTÉINE COEUR DE L'HÉPATITE B

  摘要：

  本公开部分提供了一种制备具有对乙型肝炎病毒Cp具有变构效应的化合物（I）的过程。

  公开号：

  WO2018169907A1
• 作为产物：
  描述：

  1,3-二氨基-2-羟基丙烷 、 三氟乙酸酐 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 16.0h， 以2 kg的产率得到1,3-bis-(trifluoroacetamido)-isopropanol
  参考文献：
  名称：

  [EN] PROCESS FOR MAKING HEPATITIS B CORE PROTEIN MODULATORS
  [FR] PROCÉDÉ DE PRODUCTION DE MODULATEURS DE PROTÉINE COEUR DE L'HÉPATITE B

  摘要：

  本公开部分提供了一种制备具有对乙型肝炎病毒Cp具有变构效应的化合物（I）的过程。

  公开号：

  WO2018169907A1

文献信息

• Templated molecules and methods for using such molecules
  申请人：Nuevolution A/S

  公开号：US20040049008A1

  公开（公告）日：2004-03-11

  The present invention relates to a method for synthesising templated molecules. In one aspect of the invention, the templated molecules are linked to the template which templated the synthesis thereof. The intion allows the generation of libraries which can be screened for e.g. therapeutic activity.

  本发明涉及一种合成模板分子的方法。在本发明的一个方面中，模板分子与模板连接，从而进行模板合成。该方法可生成图书馆，可对其进行筛选，例如用于治疗活性。
• TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES
  申请人：Pedersen Henrik

  公开号：US20100016177A1

  公开（公告）日：2010-01-21

  The present invention relates to a method for synthesising templated molecules. In one aspect of the invention, the templated molecules are linked to the template which templated the synthesis thereof. The intion allows the generation of libraries which can be screened for e.g. therapeutic activity.

  本发明涉及一种合成模板分子的方法。在本发明的一个方面中，模板分子与模板相连，该模板模板化了合成它们的过程。该方法允许生成可筛选例如治疗活性的库。
• Process for making Hepatitis B core protein modulators
  申请人：Assembly Biosciences, Inc.

  公开号：US11040965B2

  公开（公告）日：2021-06-22

  The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.

  本公开部分提供了一种制备化合物（I）的工艺，该化合物具有抗乙型肝炎病毒 Cp 的异生效应特性。
• pH-Triggered Release of Platinum Drugs Conjugated to Micelles via an Acid-Cleavable Linker
  作者：Sandra Binauld、Wei Scarano、Martina H. Stenzel

  DOI：10.1021/ma3012812

  日期：2012.9.11

  A new acid-degradable polymer platinum conjugate was prepared by postmodification of a POEGMEMA-b-PHEMA block copolymer obtained by RAFT polymerization. A hydrazone linkage, susceptible to hydrolytic cleavage, was formed by reaction of the carbonyl group of a diamino ligand with the hydrazide-modified copolymer. According to NMR kinetic studies, degradation of the hydrazone bond was observed to be more than 10 times faster at pH 5.5 than at pH 7.4. The platinum drug was introduced on the copolymer by permanent conjugation onto the diamino conjugation sites. The platinated amphiphilic copolymer was subsequently self-assembled into nanosized micelles of 27 nm with the platinum drug safely encapsulated in the core. Extended conjugation time however led to cross-linking and to particles of more than 1000 nm. In vitro experiments revealed a high cytotoxicity for the platinum drug-bearing small micelles compared to the polymer before conjugation. In contrast, the large particle did not show any toxicity since the size prevents endocytosis. However, endocytosis and the subsequent location of the micelles in the acidic endosomes or lysosomes are necessary to trigger the release of the toxic platinum drug. In contrast, the small drug loaded micelle exhibited a toxicity superior to the underlying low-molecular-weight drug (IC50 = 10.5 mu M vs 17 mu M) These hydrolytically degradable nanovectors constitute a promising system for a triggered release of platinum drugs.
• PROCESS FOR MAKING HEPATITIS B CORE PROTEIN MODULATORS
  申请人：Assembly Biosciences, Inc.

  公开号：US20210380577A1

  公开（公告）日：2021-12-09

  The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.